## Edoardo Mannucci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2279428/publications.pdf

Version: 2024-02-01

434 papers

22,866 citations

4388 86 h-index 126 g-index

452 all docs

452 docs citations

times ranked

452

19909 citing authors

#	Article	IF	Citations
1	Retrospective Matched Case-Control Study on the Use of CO <sub>2</sub> Laser for the Treatment of Nonhealing Diabetic Foot Ulcers: The DULCIS-2 (Diabetic ULcer, CO <sub>2</sub> Laser, and Infections) Study. International Journal of Lower Extremity Wounds, 2022, 21, 471-476.	1.1	1
2	Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 330-336.	2.6	4
3	All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 511-514.	2.6	5
4	Assessment of left ventricular global longitudinal strain in patients with type 2 diabetes: Relationship with microvascular damage and glycemic control. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 994-1000.	2.6	2
5	Periodontitis predicts HbA1c levels and glucose variability in type 1 diabetic patients: the PARODIA Florence Project study. Clinical Oral Investigations, 2022, 26, 3585-3591.	3.0	4
6	Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS). Acta Diabetologica, 2022, 59, 435-438.	2.5	12
7	CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1195-1201.	2.6	3
8	Italian guidelines for the treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 770-814.	2.6	10
9	Online group lifestyle modification programs for obesity during the COVID-19 pandemic: The EDucation ONline (EDON) retrospective study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1317-1318.	2.6	1
10	Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 529-536.	2.6	7
11	Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	4
12	Italian guidelines for the treatment of type 2 diabetes. Acta Diabetologica, 2022, 59, 579-622.	2.5	13
13	Effectiveness of lowâ€carbohydrate diets for longâ€term weight loss in obese individuals: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2022, 24, 1458-1468.	4.4	12
14	Reply to: Flaws in the meta-analysis of comparison between different types of exercise training in patients with type 2 diabetes mellitus: A letter to the editor. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	2.6	0
15	Major Amputation In Non-Healing Ulcers: Outcomes and Economic Issues. Data from a Cohort of Patients with Diabetic Foot Ulcers. International Journal of Lower Extremity Wounds, 2022, , 153473462210972.	1.1	3
16	Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 396-398.	2.6	36
17	Obesity as a risk factor for hospitalization in COronaVirus Disease-19 (COVID-19) patients: Analysis of the Tuscany regional database. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 769-773.	2.6	10
18	Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 699-704.	2.6	26

#	Article	IF	CITATIONS
19	Sodiumâ€glucose coâ€transporterâ€2 inhibitors and allâ€cause mortality: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1052-1056.	4.4	32
20	Association between different screening strategies for SARSâ€CoVâ€2 and deaths and severe disease in Italy. International Journal of Clinical Practice, 2021, 75, e13867.	1.7	2
21	Choosing the best algorithm among five thyroid nodule ultrasound scores: from performance to cytology sparing—a single-center retrospective study in a large cohort. European Radiology, 2021, 31, 5689-5698.	4.5	4
22	Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1027-1034.	2.6	11
23	Cigarette Smoking as a Predictor of Sodium–Glucose Cotransporter 2 Inhibitor–Associated Genital Infections: A Retrospective Cohort Study. Diabetes Care, 2021, 44, e127-e128.	8.6	1
24	The Florence Emotional Eating Drive (FEED): a validation study of a self-report questionnaire for emotional eating. Eating and Weight Disorders, 2021, , 1.	2.5	3
25	Rate and Predictors of Hesitancy toward SARS-CoV-2 Vaccine among Type 2 Diabetic Patients: Results from an Italian Survey. Vaccines, 2021, 9, 460.	4.4	31
26	Glucose variability and periodontal disease in type 1 diabetes: a cross-sectional studyâ€"The "PAROdontopatia e DIAbete―(PARODIA) project. Acta Diabetologica, 2021, 58, 1367-1371.	2.5	6
27	Comparison between different types of exercise training in patients with type 2 diabetes mellitus: A systematic review and network metanalysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1985-1992.	2.6	26
28	Glucose control in diabetes during home confinement for the first pandemic wave of COVID-19: a meta-analysis of observational studies. Acta Diabetologica, 2021, 58, 1603-1611.	2.5	24
29	The Role of testosterone treatment in patients with metabolic disorders. Expert Review of Clinical Pharmacology, 2021, 14, 1091-1103.	3.1	22
30	ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes. European Heart Journal Supplements, 2021, 23, C184-C195.	0.1	5
31	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2539-2546.	2.6	17
32	Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2745-2755.	2.6	21
33	Sars-CoV2 vaccine hesitancy in Italy: A survey on subjects with diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3243-3246.	2.6	22
34	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	3.2	3
35	RE: On the misuse of "weighted―composite scores: the scoring procedure of the FEED questionnaire does not indicate whether it is necessary to differentiate between the frequency of experiencing an emotion and the desire to eat in response to that emotion in the assessment of emotional eating.  Eating and Weight Disorders, 2021 1.	2.5	2
36	Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine, 2021, 74, 508-517.	2.3	12

3

#	Article	IF	CITATIONS
37	Which antidiabetic drug indications are recommended for geriatric DM patients?. Journal of Gerontology and Geriatrics, 2021, 69, 276-281.	0.5	0
38	Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 71-76.	2.6	5
39	Intestinal Hormones., 2020,, 361-381.		0
40	Glucagonâ€like peptideâ€1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated metaâ€analysis and subgroup analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 203-211.	4.4	34
41	Fournier's gangrene and sodiumâ€glucose coâ€transporterâ€2 inhibitors: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 272-275.	4.4	26
42	Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. European Neuropsychopharmacology, 2020, 32, 56-65.	0.7	20
43	Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 159, 107981.	2.8	46
44	Homeopathic Remedies in Psychiatric Disorders. Journal of Clinical Psychopharmacology, 2020, 40, 269-275.	1.4	6
45	Factors associated with the onset of major depressive disorder in adults with type 2 diabetes living in 12 different countries: results from the INTERPRET-DD prospective study. Epidemiology and Psychiatric Sciences, 2020, 29, e134.	3.9	15
46	Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1601-1608.	2.6	18
47	Impact of Influenza Vaccination on All-Cause Mortality and Hospitalization for Pneumonia in Adults and the Elderly with Diabetes: A Meta-Analysis of Observational Studies. Vaccines, 2020, 8, 263.	4.4	30
48	Combined continuous glucose monitoring and subcutaneous insulin infusion versus selfâ€monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2020, 22, 1286-1291.	4.4	10
49	Effects of probiotic supplementation during pregnancy on metabolic outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 162, 108111.	2.8	25
50	Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1106-1114.	2.6	49
51	Metabolic surgery for the treatment of type 2 diabetes: A network metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 1378-1387.	4.4	26
52	Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine, 2020, 69, 504-507.	2.3	18
53	Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus. Antioxidants, 2020, 9, 233.	5.1	7
54	Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 161, 108087.	2.8	15

#	Article	IF	CITATIONS
55	Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Acta Diabetologica, 2020, 57, 689-696.	2.5	27
56	Type 1 diabetes and periodontitis: prevalence and periodontal destruction—a systematic review. Acta Diabetologica, 2020, 57, 1405-1412.	2.5	29
57	Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 162, 108115.	2.8	8
58	Pharmacological treatment of acute-phase anorexia nervosa: Evidence from randomized controlled trials. Journal of Psychopharmacology, 2020, 34, 864-873.	4.0	22
59	Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinology, 2020, , .	1.1	11
60	Adjustment of insulin doses when switching from glargine 100ÂU/ml or detemir to degludec: an observational study. Journal of Endocrinological Investigation, 2019, 42, 319-326.	3.3	4
61	Impact of technology on glycaemic control in type 2 diabetes: A metaâ€analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes, Obesity and Metabolism, 2019, 21, 2619-2625.	4.4	31
62	Directâ€acting antivirals for HCV treatment in older patients: A systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2019, 26, 1249-1256.	2.0	17
63	Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 155, 107808.	2.8	11
64	Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 215-219.	2.6	3
65	Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 153, 138-144.	2.8	37
66	Reply to Josef Finsterer"MELAS requires broad clinical and genetic work-up― Acta Diabetologica, 2019, 56, 1089-1090.	2.5	0
67	Sodiumâ€glucose coâ€transporterâ€2 (SGLTâ€2) inhibitors and cancer: A metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2019, 21, 1871-1877.	4.4	46
68	Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6Âmonths of treatment. Acta Diabetologica, 2019, 56, 1231-1233.	2.5	4
69	Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type $1$ diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetologica, 2019, 56, 973-980.	2.5	72
70	Reply to Gaertner, K. and Frass, M Acta Diabetologica, 2019, 56, 247-247.	2.5	0
71	Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. Journal of Endocrinological Investigation, 2019, 42, 1029-1039.	3.3	33
72	PCSK9 inhibitor therapy: A systematic review and metaâ€analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 903-908.	4.4	41

#	Article	IF	CITATIONS
73	Alternative treatment or alternative to treatment? A systematic review of randomized trials on homeopathic preparations for diabetes and obesity. Acta Diabetologica, 2019, 56, 241-243.	2.5	9
74	Clinical impact of the new SIAPEC-IAP classification on the indeterminate category of thyroid nodules. Journal of Endocrinological Investigation, 2019, 42, 1-6.	3.3	16
75	Glucagon modulates proliferation and differentiation of human adipose precursors. Journal of Molecular Endocrinology, 2019, 63, 249-260.	2.5	9
76	Attending Diabetes Clinics is associated with a lower all-cause mortality. A meta-analysis of observational studies performed in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 431-435.	2.6	19
77	Short and mediumâ€ŧerm efficacy of sodium glucose coâ€ŧransporterâ€2 (SGLTâ€2) inhibitors: A metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2018, 20, 1213-1222.	4.4	41
78	Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia ― The SCELTA Trial ―. Circulation Journal, 2018, 82, 1688-1698.	1.6	23
79	Emotional eating and temperamental traits in Eating Disorders: A dimensional approach. Psychiatry Research, 2018, 264, 1-8.	3.3	13
80	Reply to the "Letter to the Editor―Ma Z -G, Yuan Y-P, Zhang X, Tang Q-Z. SGLT1: A potential target for human ischemic and hypertrophic heart? Int J Cardiol (2017). International Journal of Cardiology, 2018, 257, 38.	1.7	0
81	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. European Journal of Nutrition, 2018, 57, 679-688.	3.9	38
82	Effects of Structured Versus Unstructured Self-Monitoring of Blood Glucose on Glucose Control in Patients With Non-insulin-treated Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Science and Technology, 2018, 12, 183-189.	2.2	68
83	Sex hormoneâ€binding globulin is associated with androgen deficiency features independently of total testosterone. Clinical Endocrinology, 2018, 88, 556-564.	2.4	23
84	A case of malignant insulinoma responsive to somatostatin analogs treatment. BMC Endocrine Disorders, 2018, 18, 98.	2.2	8
85	Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies. Journal of Sexual Medicine, 2018, 15, 820-838.	0.6	91
86	Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. Journal of Sexual Medicine, 2018, 15, 1260-1271.	0.6	115
87	Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 375-377.	2.6	5
88	Autologous Cell Therapy for Peripheral Arterial Disease. Circulation Research, 2017, 120, 1326-1340.	4.5	181
89	Safety issues with glucagonâ€like peptideâ€l receptor agonists (pancreatitis, pancreatic cancer and) Tj ETQq1 1 (2017, 19, 1233-1241.	).784314 4.4	rgBT /Over
90	CO2 laser for the treatment of diabetic foot ulcers with exposed bone. A consecutive series of type 2 diabetic patients. Journal of Endocrinological Investigation, 2017, 40, 819-822.	3.3	7

#	Article	IF	Citations
91	Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. International Journal of Cardiology, 2017, 241, 302-310.	1.7	20
92	Cardiovascular safety of insulin: Between realâ€world data and reality. Diabetes, Obesity and Metabolism, 2017, 19, 1201-1204.	4.4	8
93	Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. European Urology, 2017, 72, 1000-1011.	1.9	163
94	Systematic Screening of Retinopathy in Diabetes (REaD Project): An Italian Implementation Campaign. European Journal of Ophthalmology, 2017, 27, 179-184.	1.3	9
95	Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials. International Journal of Cardiology, 2017, 240, 414-421.	1.7	36
96	Sexual dysfunction in subjects treated with inhibitors of 5αâ€reductase for benign prostatic hyperplasia: a comprehensive review and metaâ€analysis. Andrology, 2017, 5, 671-678.	3.5	72
97	Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. International Journal of Cardiology, 2017, 243, 86-90.	1.7	114
98	All-cause and cardiovascular mortality in a consecutive series of patients with diabetic foot osteomyelitis. Diabetes Research and Clinical Practice, 2017, 131, 12-17.	2.8	11
99	Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Research and Clinical Practice, 2017, 130, 53-60.	2.8	93
100	Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. Journal of Endocrinological Investigation, 2017, 40, 1251-1258.	3.3	54
101	A randomized, open-label, controlled trial to evaluate the antimicrobial and surgical effect of CO2 laser treatment in diabetic infected foot ulcers: DULCIS (diabetic ulcer, CO2 laser, and infections) study. Journal of Endocrinological Investigation, 2017, 40, 985-989.	3.3	9
102	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	11.4	231
103	Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetologica, 2017, 54, 1101-1114.	2.5	28
104	Reply to Eugenio Ventimiglia, Paolo Capogrosso, Walter Cazzaniga, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Giovanni Corona, Giulia Rastrelli, Abraham Morgentaler, Alessandra Sforza, Edoardo Mannucci, Mario Maggi. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol 2017;72:1000–11. European Urology, 2017, 72, e162-e163.	1.9	1
105	Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetologica, 2017, 54, 933-941.	2.5	59
106	Psychobiological Correlates of Vaginismus: An Exploratory Analysis. Journal of Sexual Medicine, 2017, 14, 1392-1402.	0.6	25
107	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Advances in Therapy, 2017, 34, 1791-1814.	2.9	21
108	Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?. Drug Safety, 2017, 40, 115-119.	3.2	15

#	Article	IF	CITATIONS
109	Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials. Advances in Therapy, 2017, 34, 1-40.	2.9	43
110	Is cleaved glucagon-like peptide 1 really inactive? Effects of GLP-1(9-36) on human adipose stem cells. Molecular and Cellular Endocrinology, 2017, 439, 10-15.	3.2	8
111	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A metaâ€analysis from the <scp>GetGoal</scp> programme. Diabetes, Obesity and Metabolism, 2017, 19, 248-256.	4.4	6
112	Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetologica, 2017, 54, 411-413.	2.5	10
113	Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetologica, 2017, 54, 19-36.	2.5	75
114	Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000263.	0.1	1
115	A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 231-241.	8.6	149
116	Comment on Ferrannini et al. Diabetes Care 2016;39:1108–1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115–1122. Diabetes Care, 2016, 39, e195-e195.	8.6	1
117	Differential Effects of Testosterone and Estradiol on Clitoral Function: An Experimental Study in Rats. Journal of Sexual Medicine, 2016, 13, 1858-1871.	0.6	42
118	Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes. Diabetes, 2016, 65, 2795-2809.	0.6	56
119	Perspectives in GLP-1 Research: New Targets, New Receptors. Trends in Endocrinology and Metabolism, 2016, 27, 427-438.	7.1	61
120	Cardiometabolic Risk and Female Sexuality: Focus on Clitoral Vascular Resistance. Journal of Sexual Medicine, 2016, 13, 1651-1661.	0.6	61
121	Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1071-1078.	2.6	13
122	Lower and higher-potency statins on glycemic control in type 2 diabetes: A retrospective cohort study. Diabetes Research and Clinical Practice, 2016, 120, 104-110.	2.8	9
123	Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular Diabetology, 2016, 15, 123.	6.8	52
124	High Triglycerides Predicts Arteriogenic Erectile Dysfunction and Major Adverse Cardiovascular Events in Subjects with Sexual Dysfunction. Journal of Sexual Medicine, 2016, 13, 1347-1358.	0.6	19
125	Firstâ€generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and metaâ€analysis. Andrology, 2016, 4, 1002-1009.	3.5	69
126	Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis. Diabetes Care, 2016, 39, S196-S204.	8.6	37

#	Article	IF	CITATIONS
127	Which are the male factors associated with female sexual dysfunction (FSD)?. Andrology, 2016, 4, 911-920.	3.5	32
128	Bringing the body of the iceberg to the surface: the Female Sexual Dysfunction Index-6 (FSDI-6) in the screening of female sexual dysfunction. Journal of Endocrinological Investigation, 2016, 39, 401-409.	3.3	9
129	Testosterone supplementation and body composition: results from a meta-analysis of observational studies. Journal of Endocrinological Investigation, 2016, 39, 967-981.	3.3	147
130	Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: Studies in rabbits. Molecular and Cellular Endocrinology, 2016, 424, 50-70.	3.2	22
131	Vascular and Chronological Age in Men With Erectile Dysfunction: A Longitudinal Study. Journal of Sexual Medicine, 2016, 13, 200-208.	0.6	13
132	Assessing quality of life in severe obesity: development and psychometric properties of the ORWELL-R. Eating and Weight Disorders, 2016, 21, 277-288.	2.5	4
133	How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. Journal of Endocrinological Investigation, 2016, 39, 473-484.	3.3	81
134	THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. European Journal of Endocrinology, 2016, 174, R99-R116.	3.7	171
135	Is early measurement of glycated albumin and HbA1c useful for the prediction of treatment response in type 2 diabetes?. Acta Diabetologica, 2016, 53, 669-672.	2.5	3
136	Prostanoids in patients with peripheral arterial disease. Journal of Diabetes and Its Complications, 2016, 30, 161-166.	2.3	19
137	Variability of triglyceride levels and incidence of microalbuminuria in type 2 diabetes. Journal of Clinical Lipidology, 2016, 10, 109-115.	1.5	17
138	Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetologica, 2016, 53, 35-40.	2.5	16
139	[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]. Farmeconomia E Percorsi Terapeutici, 2016, 17, 19-27.	0.1	1
140	Vascular and Chronological Age in Subjects with Erectile Dysfunction: A Cross-Sectional Study. Journal of Sexual Medicine, 2015, 12, 2303-2312.	0.6	10
141	Effect of diabetes on hospitalization for ischemic stroke and related inâ€hospital mortality: a study in Tuscany, Italy, over years 2004–2011. Diabetes/Metabolism Research and Reviews, 2015, 31, 280-286.	4.0	25
142	Cardiovascular effects of basal insulins. Drug, Healthcare and Patient Safety, 2015, 7, 113.	2.5	13
143	Effects of a Short Educational Program for the Prevention of Foot Ulcers in High-Risk Patients: A Randomized Controlled Trial. International Journal of Endocrinology, 2015, 2015, 1-5.	1.5	39
144	Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0

#	Article	IF	Citations
145	Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Molecular and Cellular Endocrinology, 2015, 402, 43-50.	3.2	24
146	Temperament and emotional eating: A crucial relationship in eating disorders. Psychiatry Research, 2015, 225, 452-457.	3.3	12
147	Prevalence of Endocrine and Metabolic Disorders in Subjects with Erectile Dysfunction: A Comparative Study. Journal of Sexual Medicine, 2015, 12, 956-965.	0.6	71
148	Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics Journal, 2015, 15, 49-54.	2.0	18
149	Trends over 8Âyears in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative. Acta Diabetologica, 2015, 52, 557-571.	2.5	36
150	Echocardiographic findings in patients with eating disorders: AÂcase–control study. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 694-696.	2.6	10
151	Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?. International Journal of Cardiology, 2015, 184, 543-544.	1.7	5
152	Obesity and late-onset hypogonadism. Molecular and Cellular Endocrinology, 2015, 418, 120-133.	3.2	128
153	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Therapy, 2015, 6, 239-256.	2.5	74
154	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. BMJ Open Diabetes Research and Care, 2015, 3, e000109.	2.8	7
155	Motivational enhancement therapy in obese patients: A promising application. Obesity Research and Clinical Practice, 2015, 9, 536-538.	1.8	2
156	Understanding EMPA-REG OUTCOME. Lancet Diabetes and Endocrinology, the, 2015, 3, 929-930.	11.4	29
157	Gender-related drug effect on several markers of oxidation stress in diabetes patients with and without complications. European Journal of Pharmacology, 2015, 766, 86-90.	3.5	19
158	Drugs for type 2 diabetes: role in the regulation of bone metabolism. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 130-4.	1.0	21
159	Erectile dysfunction and central obesity: an Italian perspective. Asian Journal of Andrology, 2014, 16, 581.	1.6	78
160	All roads bring to Rome: a different way for predicting success in the therapy of obesity through psychological features. Journal of Endocrinological Investigation, 2014, 37, 1187-1194.	3.3	6
161	Diabetes from Catecholamine Excess. Frontiers in Diabetes, 2014, , 44-51.	0.4	2
162	Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2014, 13, 1327-1351.	2.4	260

#	Article	IF	CITATIONS
163	Hypogonadism as an additional indication for bariatric surgery in male morbid obesity?. European Journal of Endocrinology, 2014, 171, 555-560.	3.7	38
164	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 38-47.	4.4	151
165	Flaccid Penile Acceleration as a Marker of Cardiovascular Risk in Men without Classical Risk Factors. Journal of Sexual Medicine, 2014, 11, 173-186.	0.6	53
166	Factors affecting spermatogenesis upon gonadotropinâ€replacement therapy: a metaâ€analytic study. Andrology, 2014, 2, 794-808.	3.5	144
167	Lack of Sexual Privacy Affects Psychological and Marital Domains of Male Sexual Dysfunction. Journal of Sexual Medicine, 2014, 11, 431-438.	0.6	9
168	Characteristics of Compensated Hypogonadism in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2014, 11, 1823-1834.	0.6	39
169	Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetologica, 2014, 51, 91-101.	2.5	100
170	Italian toasted bread (â€~bruschetta') should be carefully evaluated by people with type 1 diabetes. Acta Diabetologica, 2014, 51, 331-332.	2.5	0
171	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled studyâ€"the D.A.N.T.E (Diabetic ulcer Antimicrobial New) Tj ETQq1 1	l <b>2.</b> 58431	4 <b>4g</b> BT /Ov∈
172	Is there a practical way of predicting therapeutic success in type 2 diabetes on the basis of psychological features? Development and validation of the Psychological Predictors of Therapeutic success in Diabetes (PPTD) questionnaire. Acta Diabetologica, 2014, 51, 133-140.	2.5	2
173	Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 689-697.	2.6	167
174	Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology, 2014, 2, 741-747.	3.5	44
175	A metaâ€analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2014, 16, 833-840.	4.4	61
176	Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 48-56.	4.4	83
177	False and true pre-treatment predictors of weight loss in obese patients starting a program for lifestyle change. Eating and Weight Disorders, 2014, 19, 489-494.	2.5	3
178	Gynecomastia in subjects with sexual dysfunction. Journal of Endocrinological Investigation, 2014, 37, 525-532.	3.3	14
179	Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis. Journal of Endocrinological Investigation, 2014, 37, 477-495.	3.3	46
180	Efficacy and safety of sodium glucose coâ€transportâ€2 inhibitors in type 2 diabetes: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2014, 16, 457-466.	4.4	217

#	Article	IF	CITATIONS
181	Metformin In Vitro and In Vivo Increases Adenosine Signaling in Rabbit Corpora Cavernosa. Journal of Sexual Medicine, 2014, 11, 1694-1708.	0.6	16
182	Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit. Molecular and Cellular Endocrinology, 2014, 384, 143-154.	3.2	70
183	Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice, 2014, 103, 269-275.	2.8	81
184	Testosterone Supplementation and Sexual Function: A Meta-Analysis Study. Journal of Sexual Medicine, 2014, 11, 1577-1592.	0.6	195
185	Coronary artery disease screening in type II diabetic patients: Prognostic value of rest and stress echocardiography. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 18-23.	3.6	4
186	Lixisenatide: clinical profile and available evidence. Diabetes Management, 2014, 4, 71-84.	0.5	2
187	Association between resting energy expenditure, psychopathology and HPA-axis in eating disorders. World Journal of Clinical Cases, 2014, 2, 257.	0.8	9
188	Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. Asian Journal of Andrology, 2014, 16, 767.	1.6	11
189	Relationship of Testis Size and LH Levels with Incidence of Major Adverse Cardiovascular Events in Older Men with Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 2761-2773.	0.6	36
190	Serum PSA as a Predictor of Testosterone Deficiency. Journal of Sexual Medicine, 2013, 10, 2518-2528.	0.6	86
191	Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes. Advances in Therapy, 2013, 30, 190-202.	2.9	17
192	Targeting educational therapy for type 2 diabetes: identification of predictors of therapeutic success. Acta Diabetologica, 2013, 50, 309-317.	2.5	14
193	Dehydroepiandrosterone Supplementation in Elderly Men: A Meta-Analysis Study of Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3615-3626.	3.6	63
194	The impossible return to the Garden of Eden: The ORIGIN trial and the original sin of early insulin treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, e35-e36.	2.6	0
195	Efficacy and safety of degludec insulin: a meta-analysis of randomised trials. Current Medical Research and Opinion, 2013, 29, 339-342.	1.9	14
196	Personality features of obese women in relation to binge eating and night eating. Psychiatry Research, 2013, 207, 86-91.	3.3	27
197	The Eating Disorders Well Being Questionnaire (EDwell): a new measure of quality of life in eating disorders. Eating and Weight Disorders, 2013, 18, 11-22.	2.5	4
198	GLP-1 receptor agonist-induced polyarthritis: a case report. Acta Diabetologica, 2013, 51, 673-4.	2.5	6

#	Article	IF	Citations
199	Cardiovascular safety of sulfonylureas: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 938-953.	4.4	201
200	Risk Factors Associated with Primary and Secondary Reduced Libido in Male Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 1074-1089.	0.6	91
201	Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology, 2013, 168, 829-843.	3.7	343
202	Dipeptidyl peptidaseâ€4 inhibitors and cardiovascular risk: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 112-120.	4.4	229
203	Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index?. Fertility and Sterility, 2013, 99, 1872-1879.e1.	1.0	31
204	HbA1c levels and all-cause mortality in type 2 diabetic patients: Epidemiological evidence of the need for personalised therapeutic targets. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 300-306.	2.6	18
205	Diabetes mellitus as a risk factor for depression. A meta-analysis of longitudinal studies. Diabetes Research and Clinical Practice, 2013, 99, 98-104.	2.8	177
206	Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Current Medical Research and Opinion, 2013, 29, 369-378.	1.9	35
207	Fasting and post-prandial glucose and diabetic complication. A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 591-598.	2.6	22
208	Longâ€term treatment with Sitagliptin, a dipeptidyl peptidaseâ€4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2â€dimethylhydrazineâ€induced rats. International Journal of Cancer, 2013, 133, 2498-2503.	5.1	55
209	Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?. Diabetes Care, 2013, 36, S259-S263.	8.6	96
210	Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: cross-sectional and longitudinal analyses. Andrology, 2013, 1, 864-871.	3.5	41
211	Impaired Masturbationâ€Induced Erections: A New Cardiovascular Risk Factor for Male Subjects with Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 1100-1113.	0.6	13
212	Sociodemographic and Clinical Features of Gender Identity Disorder: An Italian Multicentric Evaluation. Journal of Sexual Medicine, 2013, 10, 408-419.	0.6	60
213	The Identification of Prediabetes Condition with ARIC Algorithm Predicts Long-Term CV Events in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2013, 10, 1114-1123.	0.6	24
214	Investigation on psychological symptoms improves ANDROTEST accuracy in predicting hypogonadism in subjects with sexual dysfunction. International Journal of Impotence Research, 2013, 25, 34-39.	1.8	8
215	Fit and Motivated: Outcome Predictors in Patients Starting a Program for Lifestyle Change. Obesity Facts, 2013, 6, 279-287.	3.4	11
216	Fat boosts, while androgen receptor activation counteracts, BPHâ€associated prostate inflammation. Prostate, 2013, 73, 789-800.	2.3	109

#	Article	IF	Citations
217	Resistin level in coronary artery disease and heart failure. Journal of Cardiovascular Medicine, 2013, 14, 150-157.	1.5	10
218	Psychopathology and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes. Scientific World Journal, The, 2013, 2013, 1-4.	2.1	4
219	Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future. International Journal of Endocrinology and Metabolism, 2013, 11, 137-44.	1.0	21
220	Depression as a Risk Factor for Diabetes. Journal of Clinical Psychiatry, 2013, 74, 31-37.	2.2	286
221	Glucagon-Like Peptide-1 and Diabetes 2012. Experimental Diabetes Research, 2012, 2012, 1-1.	3.8	4
222	Adipokines as Possible New Predictors of Cardiovascular Diseases: A Case Control Study. Journal of Nutrition and Metabolism, 2012, 2012, 1-5.	1.8	19
223	Different Moderators of Cognitive-Behavioral Therapy on Subjective and Objective Binge Eating in Bulimia Nervosa and Binge Eating Disorder: A Three-Year Follow-Up Study. Psychotherapy and Psychosomatics, 2012, 81, 11-20.	8.8	56
224	Insulin Therapy and Cancer in Type 2 Diabetes. Isrn Endocrinology, 2012, 2012, 1-12.	2.0	15
225	Bone: Incretin Hormones Perceiver or Receiver?. Experimental Diabetes Research, 2012, 2012, 1-5.	3.8	22
226	Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	79
227	Metabolic and Cardiovascular Outcomes of Fatherhood: Results from a Cohort of Study in Subjects with Sexual Dysfunction. Journal of Sexual Medicine, 2012, 9, 2785-2794.	0.6	19
228	Post-prandial glucose and diabetic complications: systematic review of observational studies. Acta Diabetologica, 2012, 49, 307-314.	2.5	42
229	Adiponectin in outpatients with coronary artery disease: Independent predictors and relationship with heart failure. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 292-299.	2.6	20
230	Lipid levels in obese and nonobese subjects as predictors of fasting and postload glucose metabolism. Journal of Clinical Lipidology, 2012, 6, 132-138.	1.5	13
231	Two Unconventional Risk Factors for Major Adverse Cardiovascular Events in Subjects with Sexual Dysfunction: Low Education and Reported Partner's Hypoactive Sexual Desire in Comparison with Conventional Risk Factors. Journal of Sexual Medicine, 2012, 9, 3227-3238.	0.6	15
232	"lt Takes Two to Tango― The Relational Domain in a Cohort of Subjects with Erectile Dysfunction (ED). Journal of Sexual Medicine, 2012, 9, 3126-3136.	0.6	45
233	Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials. Advances in Therapy, 2012, 29, 736-746.	2.9	80
234	Diabetes and sex: from pathophysiology to personalized medicine. Internal and Emergency Medicine, 2012, 7, 215-219.	2.0	25

#	Article	IF	Citations
235	Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells. Acta Diabetologica, 2012, 49, 59-63.	2.5	37
236	Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study. Acta Diabetologica, 2012, 49, 179-184.	2.5	14
237	Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovascular Diabetology, 2012, 11, 151.	6.8	23
238	Sustained Exendin-4 Secretion through Gene Therapy Targeting Salivary Glands in Two Different Rodent Models of Obesity/Type 2 Diabetes. PLoS ONE, 2012, 7, e40074.	2.5	13
239	Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?. Advances in Therapy, 2012, 29, 218-233.	2.9	41
240	Incretin-based therapies and cardiovascular risk. Current Medical Research and Opinion, 2012, 28, 715-721.	1.9	32
241	Left ventricular cavity obliteration during dobutamine stress echocardiography in diabetic patients. International Journal of Cardiovascular Imaging, 2012, 28, 1023-1033.	1.5	1
242	Stable extramarital affairs are breaking the heart. Journal of Developmental and Physical Disabilities, 2012, 35, 11-17.	3.6	15
243	Thyroid hormones and male sexual function. Journal of Developmental and Physical Disabilities, 2012, 35, 668-679.	3.6	58
244	Hormonal Association and Sexual Dysfunction in Patients with Impaired Fasting Glucose: A Cross-Sectional and Longitudinal Study. Journal of Sexual Medicine, 2012, 9, 1669-1680.	0.6	49
245	Sexual and Cardiovascular Correlates of Male Unfaithfulness. Journal of Sexual Medicine, 2012, 9, 1508-1518.	0.6	19
246	SIEDY Scale 3, a New Instrument to Detect Psychological Component in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2012, 9, 2017-2026.	0.6	66
247	Glycaemic efficacy of glucagonâ€like peptideâ€1 receptor agonists and dipeptidyl peptidaseâ€4 inhibitors as addâ€on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis. Diabetes, Obesity and Metabolism, 2012, 14, 762-767.	4.4	168
248	DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis. Advances in Therapy, 2012, 29, 14-25.	2.9	185
249	How to recognize late-onset hypogonadism in men with sexual dysfunction. Asian Journal of Andrology, 2012, 14, 251-259.	1.6	95
250	Inhibitors of $5\hat{l}$ ±-reductase-related side effects in patients seeking medical care for sexual dysfunction. Journal of Endocrinological Investigation, 2012, 35, 915-20.	3.3	15
251	Effects of antihypertensive treatments on incidence of diabetes: a case-control study. Journal of Endocrinological Investigation, 2012, 35, 135-8.	3.3	3
252	A simple ultrasound score for the identification of candidates to fine needle aspiration of thyroid nodules. Journal of Endocrinological Investigation, 2012, 35, 720-4.	3.3	5

#	Article	IF	Citations
253	Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures. Diabetes Care, 2011, 34, 2474-2476.	8.6	241
254	Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology, 2011, 165, 687-701.	3.7	376
255	Perceived Ejaculate Volume Reduction in Patients With Erectile Dysfunction: Psychobiologic Correlates. Journal of Andrology, 2011, 32, 333-339.	2.0	26
256	Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 337-353.	4.7	130
257	Inaccuracy in meta-analysis on rosiglitazone and myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, e7-e8.	2.6	3
258	Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Current Medical Research and Opinion, 2011, 27, 57-64.	1.9	198
259	Diagnostic Crossover and Outcome Predictors in Eating Disorders According to DSM-IV and DSM-V Proposed Criteria: A 6-Year Follow-Up Study. Psychosomatic Medicine, 2011, 73, 270-279.	2.0	206
260	Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2011, 13, 221-228.	4.4	309
261	Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Journal of Developmental and Physical Disabilities, 2011, 34, 41-48.	3.6	121
262	Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Journal of Developmental and Physical Disabilities, 2011, 34, 217-224.	3.6	46
263	Periodontal disease and oral hygiene habits in a type 2 diabetic population. International Journal of Dental Hygiene, 2011, 9, 68-73.	1.9	12
264	Pulse Pressure Independently Predicts Major Cardiovascular Events in Younger But Not in Older Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 247-254.	0.6	23
265	Testosterone and Metabolic Syndrome: A Meta-Analysis Study. Journal of Sexual Medicine, 2011, 8, 272-283.	0.6	310
266	Is Metabolic Syndrome a Useless Category in Subjects with High Cardiovascular Risk? Results from a Cohort Study in Men with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 504-511.	0.6	14
267	Perceived Reduced Sleep-Related Erections in Subjects with Erectile Dysfunction: Psychobiological Correlates. Journal of Sexual Medicine, 2011, 8, 1780-1788.	0.6	19
268	Body Mass Index Regulates Hypogonadism-Associated CV Risk: Results from a Cohort of Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2011, 8, 2098-2105.	0.6	48
269	Poor Response to Alprostadil ICI Test is Associated with Arteriogenic Erectile Dysfunction and Higher Risk of Major Adverse Cardiovascular Events. Journal of Sexual Medicine, 2011, 8, 3433-3445.	0.6	28
270	Type 2 diabetes mellitus and testosterone: a meta-analysis study. Journal of Developmental and Physical Disabilities, 2011, 34, 528-540.	3.6	299

#	Article	IF	Citations
271	Childhood maltreatment in subjects with male-to-female gender identity disorder. International Journal of Impotence Research, 2011, 23, 276-285.	1.8	39
272	Insulin therapy in diabetes and cancer risk: Current understanding and implications for future study. Advances in Therapy, 2011, 28, 1-18.	2.9	13
273	Predictors of response to dipeptidyl peptidaseâ€4 inhibitors: evidence from randomized clinical trials. Diabetes/Metabolism Research and Reviews, 2011, 27, 362-372.	4.0	64
274	Autologous Skin Fibroblast and Keratinocyte Grafts in the Treatment of Chronic Foot Ulcers in Aging Type 2 Diabetic Patients. Journal of the American Podiatric Medical Association, 2011, 101, 55-58.	0.3	14
275	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials. Experimental Diabetes Research, 2011, 2011, 1-10.	3.8	93
276	Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, 2011, 34, 129-131.	8.6	97
277	The use of insulin in elderly patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2011, 12, 2865-2881.	1.8	7
278	Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes, 2011, 60, 644-651.	0.6	98
279	Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities. Experimental Diabetes Research, 2011, 2011, 1-6.	3.8	29
280	Hypogonadism and metabolic syndrome. Journal of Endocrinological Investigation, 2011, 34, 557-67.	3.3	74
281	Sexual dysfunction in subjects with Klinefelter's syndrome. Journal of Developmental and Physical Disabilities, 2010, 33, 574-580.	3.6	64
282	Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. Acta Diabetologica, 2010, 47, 7-11.	2.5	6
283	Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetologica, 2010, 47, 77-81.	2.5	95
284	Prognostic value of dobutamine stress echocardiography in diabetic patients. International Journal of Cardiovascular Imaging, 2010, 26, 499-507.	1.5	5
285	Autoeroticism, Mental Health, and Organic Disturbances in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 182-191.	0.6	34
286	The Relationship of Testosterone to Prostate-Specific Antigen in Men with Sexual Dysfunction. Journal of Sexual Medicine, 2010, 7, 284-292.	0.6	38
287	Dimensional Profiles of Male to Female Gender Identity Disorder: An Exploratory Research. Journal of Sexual Medicine, 2010, 7, 2487-2498.	0.6	22
288	Low Testosterone is Associated with an Increased Risk of MACE Lethality in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1557-1564.	0.6	111

#	Article	IF	Citations
289	The Effect of Statin Therapy on Testosterone Levels in Subjects Consulting for Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1547-1556.	0.6	78
290	Male Sexuality and Cardiovascular Risk. A Cohort Study in Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 1918-1927.	0.6	113
291	Psychobiological Correlates of Women's Sexual Interest as Perceived by Patients with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 2174-2183.	0.6	17
292	Is Obesity a Further Cardiovascular Risk Factor in Patients with Erectile Dysfunction?. Journal of Sexual Medicine, 2010, 7, 2538-2546.	0.6	29
293	Priapus is Happier with Venus than with Bacchus. Journal of Sexual Medicine, 2010, 7, 2831-2841.	0.6	25
294	Severe Depressive Symptoms and Cardiovascular Risk in Subjects with Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 3477-3486.	0.6	29
295	Sexual Function in Obese Women with and without Binge Eating Disorder. Journal of Sexual Medicine, 2010, 7, 3969-3978.	0.6	40
296	Corrections to: " <i>The Journal of Sexual Medicine</i> 2010;7:2831–41.― Journal of Sexual Medicine, 2010, 7, 3803-3803.	0.6	0
297	Clinical and psychological correlates of health-related quality of life in obese patients. Health and Quality of Life Outcomes, 2010, 8, 90.	2.4	72
298	Relationship between GLPâ€1 levels and dipeptidyl peptidaseâ€4 activity in different glucose tolerance conditions. Diabetic Medicine, 2010, 27, 691-695.	2.3	36
299	Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, 2010, 33, 1997-2003.	8.6	102
300	Cognitive-Behavioral Therapy for Threshold and Subthreshold Anorexia Nervosa: A Three-Year Follow-Up Study. Psychotherapy and Psychosomatics, 2010, 79, 238-248.	8.8	50
301	Cardiac safety profile of rosiglitazone. International Journal of Cardiology, 2010, 143, 135-140.	1.7	65
302	Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 224-235.	2.6	158
303	Comparison of individual and group cognitive behavioral therapy for binge eating disorder. A randomized, three-year follow-up study. Appetite, 2010, 55, 656-665.	3.7	65
304	Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. European Journal of Endocrinology, 2009, 160, 909-917.	3.7	132
305	Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: A Meta-analysis. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 220-222.	1.2	38
306	Pulse Pressure and Prediction of Incident Foot Ulcers in Type 2 Diabetes. Diabetes Care, 2009, 32, 897-899.	8.6	25

#	Article	IF	Citations
307	Pulse Pressure, an Index of Arterial Stiffness, is Associated with Androgen Deficiency and Impaired Penile Blood Flow in Men with ED. Journal of Sexual Medicine, 2009, 6, 285-293.	0.6	61
308	Psychobiological Correlates of Extramarital Affairs and Differences Between Stable and Occasional Infidelity Among Men with Sexual Dysfunctions. Journal of Sexual Medicine, 2009, 6, 866-875.	0.6	41
309	Hypoprolactinemia: A New Clinical Syndrome in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2009, 6, 1457-1466.	0.6	123
310	Hysterical Traits are Not from the Uterus but from the Testis: A Study in Men with Sexual Dysfunction. Journal of Sexual Medicine, 2009, 6, 2321-2331.	0.6	26
311	Impairment of Couple Relationship in Male Patients with Sexual Dysfunction is Associated with Overt Hypogonadism. Journal of Sexual Medicine, 2009, 6, 2591-2600.	0.6	56
312	The Association Between Varicocele, Premature Ejaculation and Prostatitis Symptoms: Possible Mechanisms. Journal of Sexual Medicine, 2009, 6, 2878-2887.	0.6	71
313	Testosterone Partially Ameliorates Metabolic Profile and Erectile Responsiveness to PDE5 Inhibitors in an Animal Model of Male Metabolic Syndrome. Journal of Sexual Medicine, 2009, 6, 3274-3288.	0.6	133
314	Glomerular hyperfiltration and metabolic syndrome: results from the Flrenze-BAgno A Ripoli (FIBAR) Study. Acta Diabetologica, 2009, 46, 191-196.	2.5	12
315	Sulphonylureas and cancer: a case–control study. Acta Diabetologica, 2009, 46, 279-284.	2.5	171
316	Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?. Current Diabetes Reports, 2009, 9, 342-347.	4.2	8
317	Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats. Cardiovascular Diabetology, 2009, 8, 32.	6.8	23
318	Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Journal of Developmental and Physical Disabilities, 2009, 32, 587-598.	3.6	189
319	The ageâ€related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Journal of Developmental and Physical Disabilities, 2009, 32, 720-728.	3.6	101
320	Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes?. Journal of Developmental and Physical Disabilities, 2009, 32, 431-441.	3.6	81
321	Shortâ€acting insulin analogues vs. regular human insulin in type 2 diabetes: a metaâ€analysis. Diabetes, Obesity and Metabolism, 2009, 11, 53-59.	4.4	77
322	Longâ€acting insulin analogues vs. NPH human insulin in type 1 diabetes. A metaâ€analysis. Diabetes, Obesity and Metabolism, 2009, 11, 372-378.	4.4	190
323	Low Diastolic Ambulatory Blood Pressure Is Associated with Greater All ause Mortality in Older Patients with Hypertension. Journal of the American Geriatrics Society, 2009, 57, 291-296.	2.6	58
324	Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction. Journal of Sexual Medicine, 2009, 6, 1259-1269.	0.6	112

#	Article	IF	Citations
325	Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 604-612.	2.6	168
326	Amphetamine derivatives and obesity. Appetite, 2009, 52, 405-409.	3.7	18
327	Correlations between binge eating and emotional eating in a sample of overweight subjects. Appetite, 2009, 53, 418-421.	3.7	148
328	Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Laboratory Investigation, 2008, 88, 1049-1056.	3.7	44
329	Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL†cells). British Journal of Pharmacology, 2008, 153, 907-914.	5.4	16
330	Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. International Journal of Obesity, 2008, 32, 185-191.	3.4	69
331	National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. Diabetes, Obesity and Metabolism, 2008, 10, 430-435.	4.4	47
332	Pioglitazone and cardiovascular risk. A comprehensive metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2008, 10, 1221-1238.	4.4	76
333	Association between Psychiatric Symptoms and Erectile Dysfunction. Journal of Sexual Medicine, 2008, 5, 458-468.	0.6	74
334	Different Testosterone Levels Are Associated with Ejaculatory Dysfunction. Journal of Sexual Medicine, 2008, 5, 1991-1998.	0.6	137
335	Low Levels of Androgens in Men with Erectile Dysfunction and Obesity. Journal of Sexual Medicine, 2008, 5, 2454-2463.	0.6	105
336	Penile Doppler Ultrasound in Patients with Erectile Dysfunction (ED): Role of Peak Systolic Velocity Measured in the Flaccid State in Predicting Arteriogenic ED and Silent Coronary Artery Disease. Journal of Sexual Medicine, 2008, 5, 2623-2634.	0.6	120
337	Liver enzymes and risk of diabetes and cardiovascular disease: Results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism: Clinical and Experimental, 2008, 57, 387-392.	3.4	109
338	Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. International Journal of Cardiology, 2008, 126, 247-251.	1.7	10
339	Eating habits in elderly diabetic subjects: Assessment in the InCHIANTI Study. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 278-282.	2.6	9
340	Orlistat and sibutramine beyond weight loss. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 342-348.	2.6	24
341	Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 639-645.	2.6	48
342	Skin autofluorescence in type 2 diabetes: Beyond blood glucose. Diabetes Research and Clinical Practice, 2008, 79, 56-60.	2.8	44

#	Article	IF	Citations
343	Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 2008, 79, 196-203.	2.8	57
344	Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. Diabetes Research and Clinical Practice, 2008, 81, 184-189.	2.8	186
345	Winners and losers at the rosiglitazone gamble. Diabetes Research and Clinical Practice, 2008, 82, 48-57.	2.8	21
346	Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. Journal of Endocrinological Investigation, 2008, 31, 146-152.	3.3	55
347	Cardiovascular risk engines can help in selecting patients to be evaluated by dynamic penile color doppler ultrasound. Journal of Endocrinological Investigation, 2008, 31, 1058-1062.	3.3	8
348	Rosiglitazone and Risk of Cancer. Diabetes Care, 2008, 31, 1455-1460.	8.6	87
349	Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes. Diabetes Care, 2008, 31, 2154-2159.	8.6	71
350	Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients. Diabetes Care, 2008, 31, 199-203.	8.6	177
351	Treatment with Insulin Secretagogues and Cancer-Related Mortality in Type 2 Diabetic Patients A Retrospective Cohort Study. Experimental and Clinical Endocrinology and Diabetes, 2008, 116, 184-189.	1.2	25
352	Metabolic Syndrome and Cardiovascular Mortality in Older Type 2 Diabetic Patients: A Longitudinal Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 646-649.	3.6	10
353	The Diabetic Person Beyond a Foot Ulcer. Journal of the American Podiatric Medical Association, 2008, 98, 130-136.	0.3	79
354	Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients. Stroke, 2007, 38, 1154-1160.	2.0	98
355	Is Basal Insulin Always the First Choice for Initiation of Insulin Therapy in Type 2 Diabetic Patients?. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 339-340.	1.2	0
356	Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women. Diabetes Care, 2007, 30, 1241-1247.	8.6	144
357	Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes: Response to Nathan et al Diabetes Care, 2007, 30, 193-194.	8.6	4
358	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 32-40.	2.6	16
359	How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 719-726.	2.6	22
360	A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Research and Clinical Practice, 2007, 78, 132-135.	2.8	20

#	Article	IF	Citations
361	Group versus individual cognitive-behavioral treatment for obesity: Results after 36 months. Eating and Weight Disorders, 2007, 12, 147-153.	2.5	22
362	Are comorbidity indices useful in predicting all-cause mortality in Type 2 diabetic patients? Comparison between Charlson index and disease count. Aging Clinical and Experimental Research, 2007, 19, 492-496.	2.9	23
363	National Cholesterol Educational Program and International Diabetes Federation diagnostic criteria for metabolic syndrome in an Italian cohort: Results from the FIBAR Study. Journal of Endocrinological Investigation, 2007, 30, 925-930.	3.3	12
364	Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. Journal of Endocrinological Investigation, 2007, 30, RC26-RC30.	<b>3.</b> 3	90
365	Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes/Metabolism Research and Reviews, 2007, 23, 479-484.	4.0	93
366	Prognostic value of serum liver enzymes levels in type 2 diabetic patients. Diabetes/Metabolism Research and Reviews, 2007, 23, 625-630.	4.0	17
367	IDF and ATPâ€III definitions of metabolic syndrome in the prediction of all ause mortality in type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2007, 9, 350-353.	4.4	41
368	Metabolic syndrome and pulse pressure. Diabetes, Obesity and Metabolism, 2007, 9, 600-602.	4.4	12
369	ORIGINAL RESEARCHâ€"ENDOCRINOLOGY: A Comparison of NCEP-ATPIII and IDF Metabolic Syndrome Definitions with Relation to Metabolic Syndrome-Associated Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 789-796.	0.6	81
370	ORIGINAL RESEARCHâ€"ENDOCRINOLOGY: NCEP-ATPIII-Defined Metabolic Syndrome, Type 2 Diabetes Mellitus, and Prevalence of Hypogonadism in Male Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 1038-1045.	0.6	99
371	Effect of Hyperprolactinemia in Male Patients Consulting for Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 1485-1493.	0.6	116
372	Rosiglitazone and cardiovascular risk. New England Journal of Medicine, 2007, 357, 938; author reply 939-40.	27.0	6
373	Aggressiveness, Anger and Eating Disorders: A Review. Psychopathology, 2006, 39, 55-68.	1.5	44
374	Incidence and prognostic significance of hypoglycemia in hospitalized non-diabetic elderly patients. Aging Clinical and Experimental Research, 2006, 18, 446-451.	2.9	19
375	Assessment of the Relational Factor in Male Patients Consulting for Sexual Dysfunction: The Concept of Couple Sexual Dysfunction. Journal of Andrology, 2006, 27, 795-801.	2.0	83
376	Psycho-Biological Correlates of Free-Floating Anxiety Symptoms in Male Patients With Sexual Dysfunctions. Journal of Andrology, 2006, 27, 86-93.	2.0	88
377	Psychobiological Correlates of Delayed Ejaculation in Male Patients With Sexual Dysfunctions. Journal of Andrology, 2006, 27, 453-458.	2.0	84
378	Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes. Journal of Endocrinological Investigation, 2006, 29, 619-624.	3.3	14

#	Article	lF	Citations
379	Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. American Heart Journal, 2006, 151, 1094-1100.	2.7	23
380	Feasibility of Multiparametric Screening for Glucose Tolerance. Laboratory Medicine, 2006, 37, 352-357.	1.2	0
381	Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. International Journal of Impotence Research, 2006, 18, 190-197.	1.8	158
382	Cystatin C reference values and aging. Clinical Biochemistry, 2006, 39, 658-661.	1.9	45
383	ANDROTEST©: A Structured Interview for the Screening of Hypogonadism in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2006, 3, 706-715.	0.6	115
384	Psychobiologic Correlates of the Metabolic Syndrome and Associated Sexual Dysfunction. European Urology, 2006, 50, 595-604.	1.9	223
385	Pulse pressure and mortality in hypertensive type 2 diabetic patients. A cohort study. Diabetes/Metabolism Research and Reviews, 2006, 22, 172-175.	4.0	26
386	Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes/Metabolism Research and Reviews, 2006, 22, 477-482.	4.0	90
387	Is the Third Component of Metabolic Syndrome Really Predictive of Outcomes in Type 2 Diabetic Patients?. Diabetes Care, 2006, 29, 2515-2517.	8.6	17
388	Metformin Beyond Diabetes: New Life for an Old Drug. Current Diabetes Reviews, 2006, 2, 307-315.	1.3	33
389	Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. International Journal of Obesity, 2006, 30, 1132-1137.	3.4	93
390	Effect of lower diagnostic thresholds on estimates of prevalence of impaired fasting glucose (IFG). Diabetic Medicine, 2005, 22, 353-354.	2.3	4
391	Difficulties in achieving vs maintaining erection: organic, psychogenic and relational determinants. International Journal of Impotence Research, 2005, 17, 252-258.	1.8	21
392	Psychobiological correlates of smoking in patients with erectile dysfunction. International Journal of Impotence Research, 2005, 17, 527-534.	1.8	36
393	The impotent couple: low desire. Journal of Developmental and Physical Disabilities, 2005, 28, 46-52.	3.6	77
394	Long-term interactive group education for type 1 diabetic patients. Acta Diabetologica, 2005, 42, 1-6.	2.5	15
395	Eating disorders in patients with Type 1 diabetes: A meta-analysis. Journal of Endocrinological Investigation, 2005, 28, 417-419.	3.3	203
396	Seizures as the only clinical manifestation of reactive hypoglycemia: A case report. Journal of Endocrinological Investigation, 2005, 28, 940-941.	3.3	13

#	Article	IF	CITATIONS
397	Glucagon-like peptide 1 (GLP-1) and metabolic diseases. Journal of Endocrinological Investigation, 2005, 28, 746-758.	3.3	31
398	Restoration of Cardiomyocyte Functional Properties by Angiotensin II Receptor Blockade in Diabetic Rats. Diabetes, 2004, 53, 1927-1933.	0.6	41
399	The prevalence of coronary heart disease in TypeÂ2 diabetic patients in Italy: the DAI study. Diabetic Medicine, 2004, 21, 738-745.	2.3	29
400	Psycho-biological correlates of hypoactive sexual desire in patients with erectile dysfunction. International Journal of Impotence Research, 2004, 16, 275-281.	1.8	104
401	Aging and pathogenesis of erectile dysfunction. International Journal of Impotence Research, 2004, 16, 395-402.	1.8	89
402	Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study. International Journal of Obesity, 2004, 28, 1456-1462.	3.4	54
403	Isolated ambulatory hypertension is common in outpatients referred to a hypertension centre. Journal of Human Hypertension, 2004, 18, 897-903.	2.2	31
404	Age-Related Changes in Treatment Strategies for Acute Myocardial Infarction: A Population-Based Study. Journal of the American Geriatrics Society, 2004, 52, 1355-1360.	2.6	23
405	Organic, Relational and Psychological Factors in Erectile Dysfunction in Men with Diabetes Mellitus. European Urology, 2004, 46, 222-228.	1.9	86
406	Psycho-Biological Correlates of Rapid Ejaculation in Patients Attending an Andrologic Unit for Sexual Dysfunctions. European Urology, 2004, 46, 615-622.	1.9	158
407	All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes/Metabolism Research and Reviews, 2004, 20, 44-47.	4.0	52
408	Indexes of abdominal adiposity in patients with Type 2 diabetes. Journal of Endocrinological Investigation, 2004, 27, 535-540.	3.3	13
409	The metabolic syndrome in treatment-seeking obese persons. Metabolism: Clinical and Experimental, 2004, 53, 435-440.	3.4	49
410	Fasting plasma glucose and glycated haemoglobin in the screening of diabetes and impaired glucose tolerance. Acta Diabetologica, 2003, 40, 181-186.	2.5	49
411	Comparison among different insulin sensitivity indices in obese patients. Diabetic Medicine, 2003, 20, 462-466.	2.3	11
412	Structured interview on erectile dysfunction (SIEDYÂ $\odot$ ): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. International Journal of Impotence Research, 2003, 15, 210-220.	1.8	170
413	Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochemical and Biophysical Research Communications, 2003, 310, 28-31.	2.1	68
414	Plasma Adiponectin and Hyperglycaemia in Diabetic Patients. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1131-5.	2.3	21

#	Article	IF	Citations
415	Eating Disorders and Body Image Disturbances among Ballet Dancers, Gymnasium Users and Body Builders. Psychopathology, 2003, 36, 247-254.	1.5	139
416	Finger Sepsis in Two Poorly Controlled Diabetic Patients With Reuse of Lancets. Diabetes Care, 2002, 25, 1103-1103.	8.6	18
417	Use of an Oxidized Regenerated Cellulose and Collagen Composite for Healing of Chronic Diabetic Foot Ulcers: A report of two cases. Diabetes Care, 2002, 25, 1892-1893.	8.6	4
418	Eating behavior in obese patients with and without type 2 diabetes mellitus. International Journal of Obesity, 2002, 26, 848-853.	3.4	70
419	Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects. Diabetes Care, 2001, 24, 489-494.	8.6	281
420	Fluoxetine and Fluvoxamine Combined with Individual Cognitive-Behaviour Therapy in Binge Eating Disorder: A One-Year Follow-Up Study. Psychotherapy and Psychosomatics, 2001, 70, 298-306.	8.8	124
421	Cognitive-Behavioural Therapy for Bulimia nervosa and Binge Eating Disorder. Psychotherapy and Psychosomatics, 2000, 69, 287-295.	8.8	46
422	Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabetic Medicine, 2000, 17, 713-719.	2.3	97
423	Comparison between 2 insulin sensitivity indexes in obese patients. Diabetes Care, 2000, 23, 1042-1043.	8.6	6
424	Screening for binge eating disorder in obese outpatients. Comprehensive Psychiatry, 2000, 41, 111-115.	3.1	139
425	Medium-term hypoglycaemic effects of two different oral formulations of gliclazide. Diabetic Medicine, 1999, 16, 618-619.	2.3	6
426	Comparison of ADA and WHO screening methods for diabetes mellitus in obese patients. Diabetic Medicine, 1999, 16, 579-585.	2.3	21
427	Quality of life and overweight. Addictive Behaviors, 1999, 24, 345-357.	3.0	161
428	Further data on the comparison between World Health Organization and American Diabetes Association diagnostic criteria DIAINF Study Group. Diabetes Care, 1999, 22, 1755-1757.	8.6	5
429	Relationship between leptin and oestrogens in healthy women. European Journal of Endocrinology, 1998, 139, 198-201.	3.7	88
430	Screening for diabetes in obese patients using the new diagnostic criteria. Diabetes Care, 1998, 21, 468-469.	8.6	6
431	Assessment of Basic Symptoms in Schizophrenia, Schizoaffective and Bipolar Disorders. Psychopathology, 1997, 30, 53-58.	1.5	29
432	Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes. Journal of Receptor, Ligand and Channel Research, 0, , 105.	0.7	1

#	Article	IF	CITATIONS
433	Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Endocrine Abstracts, 0, , .	0.0	1
434	Metformin in vitro and in vivo increases adenosine signalling in rabbit corpora cavernosa. Endocrine Abstracts, 0, , .	0.0	O